Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, has entered into a definitive agreement for a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The offering involves the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. Concurrently, the company announced a private placement of unregistered warrants and revealed its intention to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.
The registered direct offering is a significant capital-raising move for Lantern Pharma, providing funds to support its ongoing clinical programs and the development of its AI capabilities. The company’s pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The planned spin-off of withZeta.ai into an independent entity marks a strategic shift for Lantern Pharma. withZeta.ai, described as a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community. This move could unlock value for shareholders by creating a standalone business focused on AI-driven drug discovery and development, with a new revenue stream from subscriptions. The offering and spin-off are expected to position Lantern to capitalize on the growing demand for AI in precision oncology.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company’s proprietary RADR platform leverages AI and machine learning to transform the development of cancer therapies. The details of the offering and spin-off are outlined in the full press release available at https://ibn.fm/6Dy4I.
The implications of this announcement are multifaceted. For Lantern Pharma, the capital infusion provides runway for its clinical trials and AI development. For the broader biomedical community, the commercialization of withZeta.ai could accelerate drug discovery by offering a powerful AI tool on a subscription basis. The spin-off may also attract investors focused on AI technology, separate from the risks of clinical-stage drug development. This strategic move underscores the increasing integration of AI in precision oncology and the potential for such platforms to generate independent value.
